Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

NCT04895046 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funder decision

Conditions

HRD
Cholangiocarcinoma
Metastatic Cancer

Interventions

DRUG: Niraparib
DRUG: Dostarlimab
DRUG: Dostarlimab

Sponsor

Walid Shaib, MD

Collaborators

[object Object]
[object Object]